Cargando…
Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database
The maximum dosage of methotrexate (MTX) for treatment of rheumatoid arthritis (RA) formally approved in Japan is 8 mg/week. We intended to examine the efficacy and safety of MTX at dosages over 8 mg/week in Japanese rheumatoid arthritis patients using the large Institute of Rheumatology, Rheumatoid...
Autores principales: | Seto, Yohei, Tanaka, Eiichi, Inoue, Eisuke, Nakajima, Ayako, Taniguchi, Atsuo, Momohara, Shigeki, Yamanaka, Hisashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236829/ https://www.ncbi.nlm.nih.gov/pubmed/21424533 http://dx.doi.org/10.1007/s10165-011-0445-4 |
Ejemplares similares
-
PADI4 and HLA-DRB1 Are Genetic Risks for Radiographic Progression in RA Patients, Independent of ACPA Status: Results from the IORRA Cohort Study
por: Suzuki, Taku, et al.
Publicado: (2013) -
An Osteoprotegerin Gene Polymorphism Is Associated with an Increased Risk of Hip Fracture in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Observational Cohort Study
por: Yoshida, Shinji, et al.
Publicado: (2014) -
Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort
por: Yano, Koichiro, et al.
Publicado: (2018) -
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data
por: Tanaka, Eiichi, et al.
Publicado: (2022) -
Response to ‘Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study’
por: Ikari, Katsunori, et al.
Publicado: (2014)